Advanced Linker Technology for Antibody-Drug Conjugates
Lead Research Organisation:
University of Cambridge
Department Name: Chemistry
Abstract
Antibody-drug conjugates (ADCs) are a promising class of biopharmaceuticals, that combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs came to the market, ADC technologies have emerged, such as antibody engineering. However, there remain gaps in the development of linker optimisation and novel conjugation strategies. This project will focus on new linker technologies that will help to promote conjugate homogeneity and overall ADC stability.
People |
ORCID iD |
David Spring (Primary Supervisor) | |
Friederike Dannheim (Student) |
Publications
Walsh S
(2021)
Site-selective modification strategies in antibody-drug conjugates
in Chemical Society Reviews